ZYPREXA (olanzapine) is a psychotropic agent that belongs to the thienobenzodiazepine class.
ZYPREXA is indicated for the following:
Oral ZYPREXA is indicated for the treatment of schizophrenia.
The efficacy of ZYPREXA was established in short-term (6-week) controlled trials of schizophrenic inpatients (see CLINICAL PHARMACOLOGY).
The effectiveness of oral ZYPREXA at maintaining a treatment response in schizophrenic patients who had been stable on ZYPREXA for approximately 8 weeks and were then followed for a period of up to 8 months has been demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY). Nevertheless, the physician who elects to use ZYPREXA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).
-- Oral ZYPREXA is indicated for the treatment of acute mixed or manic episodes associated with Bipolar I Disorder.
The efficacy of ZYPREXA was established in two placebo-controlled trials (one 3-week and one 4-week) with patients meeting DSM-IV criteria for Bipolar I Disorder who currently displayed an acute manic or mixed episode with or without psychotic features (see CLINICAL PHARMACOLOGY).
-- The benefit of maintaining bipolar patients on monotherapy with oral ZYPREXA after achieving a responder status for an average duration of two weeks was demonstrated in a controlled trial (see Clinical Efficacy Data under CLINICAL PHARMACOLOGY). The physician who elects to use ZYPREXA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).
-- The combination of oral ZYPREXA with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.
The efficacy of ZYPREXA in combination with lithium or valproate was established in two placebo-controlled (6-week) trials with patients meeting DSM-IV criteria for Bipolar I Disorder who currently displayed an acute manic or mixed episode with or without psychotic features (see CLINICAL PHARMACOLOGY).
AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
ZYPREXA IntraMuscular is indicated for the treatment of agitation associated with schizophrenia and bipolar I mania. "Psychomotor agitation" is defined in DSM-IV as "excessive motor activity associated with a feeling of inner tension." Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation.
The efficacy of ZYPREXA IntraMuscular for the treatment of agitation associated with schizophrenia and bipolar I mania was established in 3 short-term (24 hours) placebo-controlled trials in agitated inpatients with schizophrenia or Bipolar I Disorder (manic or mixed episodes) (see CLINICAL PHARMACOLOGY).
Media Articles Related to Zyprexa (Olanzapine)
Zyprexa in schizophrenia shown to prevent brain loss
Source: The Doctors Lounge - Psychiatry
Zyprexa (olanzapine) was found to decrease brain loss in schizophrenia patients according to the Archives of General Psychiatry.
Source: MedicineNet Biorhythms Specialty [2014.01.08]
Title: ICU Psychosis
Category: Diseases and Conditions
Created: 12/10/1998 9:43:00 AM
Last Editorial Review: 1/8/2014 12:00:00 AM
New Drug Shows Early Promise in Treating Parkinson's Psychosis
Source: MedicineNet clozapine Specialty [2013.11.01]
Title: New Drug Shows Early Promise in Treating Parkinson's Psychosis
Category: Health News
Created: 10/31/2013 7:36:00 PM
Last Editorial Review: 11/1/2013 12:00:00 AM
Childhood nightmare frequency linked to psychotic experience risk
Source: Health News from Medical News Today [2014.03.08]
Frequent nightmares in childhood could indicate an increased risk of psychosis, according to research from the University of Warwick in the UK. The study authors have published their findings in the journal Sleep.It is very common for young children to have nightmares. Having bad dreams is a normal part of growing up, and the frequency of nightmares usually decreases as the child grows older.Nightmares happen during REM (rapid eye movement) sleep - one of the five stages that most people experience over the course of a night's sleep.
The death of a loved one in childhood 'affects adult mental health'
Source: Bipolar News From Medical News Today [2014.01.22]
A new study published in the British Medical Journal finds a small but significant increase in psychosis risk for people who suffer the loss of a family member in childhood.
Published Studies Related to Zyprexa (Olanzapine)
Association of common variations in the norepinephrine transporter gene with
response to olanzapine-fluoxetine combination versus continued-fluoxetine
treatment in patients with treatment-resistant depression: a candidate gene
CONCLUSIONS: Our findings further support the hypothesis that the synergistic
Factors associated with non-completion in a double-blind randomized controlled
trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic
High rates of attrition have been reported in randomized controlled trials of
patients with severe psychiatric illness, including psychotic depression (MDpsy). The purpose of this study is to examine factors associated with overall attrition
and with subtypes of attrition in the Study of the Pharmacotherapy of Psychotic
Efficacy and safety of olanzapine in the treatment of Japanese patients with
bipolar I disorder in a current manic or mixed episode: a randomized,
double-blind, placebo- and haloperidol-controlled study. 
manic/mixed episode... CONCLUSIONS: This was the first study to evaluate an atypical antipsychotic in
Risperidone and olanzapine versus another first generation antipsychotic in
patients with schizophrenia inadequately responsive to first generation
CONCLUSIONS: Haloperidol or trifluoperazine demonstrated similar efficacy as
A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. [2011.10]
CONCLUSIONS: Olanzapine 5-10 mg/d showed a clinically modest advantage over placebo in the treatment of overall borderline psychopathology. This advantage in effectiveness should be weighed against the risk of adverse events (particularly weight gain), which were consistent with the known safety profile of olanzapine. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00088036. (c) Copyright 2011 Physicians Postgraduate Press, Inc.
Clinical Trials Related to Zyprexa (Olanzapine)
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia [Completed]
This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine
depot works compared to oral olanzapine; evaluate the safety and tolerability of IM
olanzapine depot compared to oral olanzapine; evaluate different doses of IM olanzapine
depot; and determine the blood levels of IM olanzapine depot in patients at different points
in time after an injection.
Effects of Modafinil on Olanzapine Weight Gain [Completed]
This study is designed as a 3 week, randomized, double blind, placebo controlled, trial.
Olanzapine and modafinil will be titrated to 10mg and 200mg respectively. Feeding lab
assessments will be conducted at baseline and endpoint. Assessments of hunger/satiety,
kilocalories consumed and weight will be obtained. Plasma ghrelin and PYY3-36 levels will be
drawn at baseline and endpoint prior to breakfast and two hours post.
Study hypothesis: The modafinil/olanzapine group will gain less weight than the
olanzapine/placebo group over three weeks of drug intake.
Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia [Active, not recruiting]
To compare the health outcome of patients with schizophrenia, who are at risk for relapse,
when treated with a long acting injection form of olanzapine versus treatment with oral
Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects [Recruiting]
The main purpose of this study is to determine whether the opioid antagonist naltrexone is
helpful in ameliorating the weight gain and other adverse metabolic side effects experienced
by schizophrenic patients taking the second generation antipsychotic (SGA) Zyprexa.
Schizophrenics may have an altered/enhanced endogenous opioidergic drive, and because of
this, normally painful stimuli will be sensed as less painful in schizophrenics vs. healthy
controls. A secondary hypothesis for this study is that naltrexone augmentation of Zyprexa
will normalize subjective pain ratings. Our tertiary objective is to examine the safety and
tolerability of naltrexone in Zyprexa-treated patients with schizophrenia.
Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy [Recruiting]
A study to examine whether an antipsychotic combination treatment of olanzapine and
amisulpride is more effective than olanzapine and amisulpride alone.
Reports of Suspected Zyprexa (Olanzapine) Side Effects
Weight Increased (199),
OFF Label USE (147),
Diabetes Mellitus (117),
Confusional State (68),
Pneumonia (61), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 7 ratings/reviews, Zyprexa has an overall score of 6. The effectiveness score is 7.71 and the side effect score is 6.86. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
Zyprexa review by 20 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || depression|
|Dosage & duration:|| || 10mg taken every night for the period of six years|
|Other conditions:|| || anorexia nervosa|
|Other drugs taken:|| || Lamictal, birth control (Jolessa)|
|Benefits:|| || Went from severely depressed before starting the medication to almost entirely free of depression a week after starting the medication; helped with insomnia.|
|Side effects:|| || drowsiness in the beginning, but I quickly got used to it.|
|Comments:|| || I entered a hospuital six years ago for suicidality; I wasn't sleeping, I wasn't eating (I had anorexia nervosa), and I was extremely depressed. I started taking 10mg of Zyprexa the first night I was there. I was really drowsy all the next day, but it waned over a few days (now it doesn't affect my energy level at all.) In about a week, my depression just lifted. This medicine has worked miracles for me- I've been depression-free since starting it- and I wouldn't go off it for any reason.|
Zyprexa review by care giver of 81 year old male patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Severe Side Effects|
|Condition / reason:|| || agitation management r/t Lewy Body Syndrome Demen|
|Dosage & duration:|| || 20mg taken x1 / daily for the period of 5 years|
|Other conditions:|| || B/P ,Diabetes, obesity, SVT's,osteoporosis|
|Other drugs taken:|| || ASA, Cardia, Fosamax, glyburide,Lorazepam, Metformin, Namenda,Razadyne, Simvastatin, Zetia, Plavix |
|Benefits:|| || The Zyprexa minimized agitative outbursts|
|Side effects:|| || The pt developed severe "gait freezing" , gait shuffling, severe muscle weakness, and gereral stupor |
|Comments:|| || Since many of these s/s are also s/s of the disease-Lewy Body Syndrome Demenia, it took research and experimentation by me and the MD to realize that it was the med adn not the disease in this case. The pt has been taken off the drug and no longer has these pronounced s/s.|
Zyprexa review by 43 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Ineffective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || Bipolar Disorder Type II|
|Dosage & duration:|| || 15mg taken 3 times per day for the period of approximately 2 years|
|Other conditions:|| || none|
|Other drugs taken:|| || Effexor XR & Tegretol (Carbamazapine)|
|Benefits:|| || While taking Zyprexa, I never experienced any episodes of hypomania (low mania) which typically accompany Bipolar Type II; however, I attribute this mostly to the fact that Zyprexa is very sedating. It should be noted that although Zyprexa is classified as an A-typical antipsychotic, it is also used as a mood stabilizer in patients with Bipolar Disorder. |
|Side effects:|| || Increased appetite which of course lead to weight gain which caused me to feel depressed! I am not exaggerating when I say my appetite was almost insatiable. Excessive sleepiness during the day which caused me to actually start falling asleep while talking to someone on several occassions. It also made me feel almost "numb" emotionally. Sedation along with an insatiable appetite caused me to gain over 25 pounds.|
|Comments:|| || My psychiatrist prescribed Zyprexa to help with the mood swings of Bipolar Disorder. I am classified as Bipolar Type II because I do not experience the extreme highs of mania (manic episodes) that accompany Bipolar Type I. I do, however, experience hypomania (hypo meaning low) so my moods still swing from highs to the extreme lows of depression. |
Page last updated: 2014-03-08